Abstract

BackgroundThe gold standard for the diagnosis of central precocious puberty (CPP) is gonadotropin-releasing hormone (GnRH) or GnRH analogs (GnRHa) stimulation test. But the stimulation test is time-consuming and costly. Our objective was to develop a risk score model readily adoptable by clinicians and patients.MethodsA cross-sectional study based on the electronic medical record system was conducted in the Children’s Hospital, Fudan University, Shanghai, China from January 2010 to August 2016. Patients with precocious puberty were randomly split into the training (n = 314) and validation (n = 313) sample. In the training sample, variables associated with CPP (P < 0.2) in univariate analyses were introduced in a multivariable logistic regression model. Prediction model was selected using a forward stepwise analysis. A risk score model was built with the scaled coefficients of the model and tested in the validation sample.ResultsCPP was diagnosed in 54.8% (172/314) and 55.0% (172/313) of patients in the training and validation sample, respectively. The CPP risk score model included age at the onset of puberty, basal luteinizing hormone (LH) concentration, largest ovarian volume, and uterine volume. The C-index was 0.85 (95% CI: 0.81–0.89) and 0.86 (95% CI: 0.82–0.90) in the training and the validation sample, respectively. Two cut-off points were selected to delimitate a low- (< 10 points), median- (10–19 points), and high-risk (≥ 20 points) group.ConclusionsA risk score model for the risk of CPP had a moderate predictive performance, which offers the advantage of helping evaluate the requirement for further diagnostic tests (GnRH or GnRHa stimulation test).

Highlights

  • The gold standard for the diagnosis of central precocious puberty (CPP) is gonadotropin-releasing hormone (GnRH) or GnRH analogs (GnRHa) stimulation test

  • Patients were included according to the criteria as follows: (1) girls with a diagnosis of precocious puberty; (2) girls at the age of 8 years old or less when she was diagnosed; (3) hormone assay and pelvic ultrasonography performed in the Children’s Hospital, Fudan University; (4) pelvic ultrasonography performed within 1 week of the GnRHa stimulation test

  • Patients with secondary precocious puberty, e.g. precocious puberty due to CNS lesions or ovarian cyst were not included in the study, because hypothalamic-pituitary-gonadal axis (HPGA), target organs and the results of GnRHa stimulation test may all be affected by the primary diseases

Read more

Summary

Introduction

The gold standard for the diagnosis of central precocious puberty (CPP) is gonadotropin-releasing hormone (GnRH) or GnRH analogs (GnRHa) stimulation test. Precocious puberty, defined as the onset of pubertal development before age 8 years in girls and 9 years in boys [1], has a prevalence of 0.43% in China and 0.01– 0.02% in America girls [2, 3]. Only cases of central precocious puberty (CPP) may need a gonadotropinreleasing hormone analogs (GnRHa) therapy [1]. With increased awareness of the importance of early treatment of CPP, more and more females with subtle signs of precocious puberty were diagnosed as precocious pubertal development [7]. To distinguish CPP from PPP and benign variants of sexual precocity is of great importance

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call